These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 18297140)
41. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. Paneni F; Lüscher TF Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186 [TBL] [Abstract][Full Text] [Related]
42. Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues. Eldor R; Raz I Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():85-9. PubMed ID: 23280872 [TBL] [Abstract][Full Text] [Related]
43. Pharmacologic Agents Used to Treat Type 2 Diabetes. Moran KJ; Burson R Home Healthc Now; 2017; 35(7):394-395. PubMed ID: 28650371 [No Abstract] [Full Text] [Related]
44. [New therapies for diabetes: beyond injectable insulin and oral antidiabetics]. Alfonso JE; Ariza ID Rev Assoc Med Bras (1992); 2008; 54(5):447-54. PubMed ID: 18989567 [TBL] [Abstract][Full Text] [Related]
45. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Fitchett DH; Udell JA; Inzucchi SE Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447 [TBL] [Abstract][Full Text] [Related]
46. ABC of diabetes. Treatment. Watkins PJ Br Med J (Clin Res Ed); 1982 Jun; 284(6332):1853-5. PubMed ID: 6805729 [No Abstract] [Full Text] [Related]
47. Recommendations on the effect of antidiabetic drugs in bone. Rozas-Moreno P; Reyes-García R; Jódar-Gimeno E; Varsavsky M; Luque-Fernández I; Cortés-Berdonces M; Muñoz-Torres M; Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():1-6. PubMed ID: 28440761 [TBL] [Abstract][Full Text] [Related]
48. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Dankner R; Roth J Diabet Med; 2020 Feb; 37(2):194-202. PubMed ID: 31769894 [TBL] [Abstract][Full Text] [Related]
49. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. McReelis KD; Lovshin JA Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013 [No Abstract] [Full Text] [Related]
50. Dissecting the interaction between COVID-19 and diabetes mellitus. Chee YJ; Tan SK; Yeoh E J Diabetes Investig; 2020 Sep; 11(5):1104-1114. PubMed ID: 32558211 [TBL] [Abstract][Full Text] [Related]
51. What to add in with metformin in type 2 diabetes? Petrie JR; Adler A; Vella S QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663 [TBL] [Abstract][Full Text] [Related]
52. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427 [No Abstract] [Full Text] [Related]
53. Clinical decisions. Management of type 2 diabetes. Goldberg RB; Holman R; Drucker DJ N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869 [No Abstract] [Full Text] [Related]
54. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes]. Scheen AJ; Paquot N Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100 [TBL] [Abstract][Full Text] [Related]
55. [Pharmacologic treatment of diabetes]. De Montigny P; Clerc C; Descarpentries C Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094 [No Abstract] [Full Text] [Related]
56. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Singh AK; Singh R Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238 [TBL] [Abstract][Full Text] [Related]
57. Treating type 2 diabetes: targeting the many causative factors. Sutherland JE; Hoehns JD J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823 [No Abstract] [Full Text] [Related]